TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies
{{output}}
TP53 mutations drive oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), impairing p53-regulated functions such as apoptosis, immune surveillance, and genomic stability, leading to immune evasion and met... ...
